

# Herbert Y Meltzer

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/9527878/publications.pdf](https://exaly.com/author-pdf/9527878/publications.pdf)

Version: 2025-02-01

217  
papers

18,417  
citations

12193

64  
h-index

9868

132  
g-index

233  
all docs

233  
docs citations

233  
times ranked

12458  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic markers of early response to lurasidone in acute schizophrenia. <i>Pharmacogenomics Journal</i> , 2025, 25, .	3.1	0
2	Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study. <i>Pharmacogenomics Journal</i> , 2023, 23, 119-126.	3.1	3
3	Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment. <i>ELife</i> , 2023, 12, .	1.6	0
4	Author Response: Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment. , 2023, , .		0
5	Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom. <i>Translational Psychiatry</i> , 2022, 12, .	5.7	6
6	Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents. <i>Schizophrenia</i> , 2022, 8, .	3.3	2
7	Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice. <i>Behavioural Brain Research</i> , 2022, 432, 113964.	2.3	2
8	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. <i>Drug Development Research</i> , 2021, 82, 678-684.	3.5	5
9	Contrasting Typical and Atypical Antipsychotic Drugs. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 3-13.	1.3	19
10	An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system. <i>Science Advances</i> , 2021, 7, .	11.3	10
11	Depolarizing GABA current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia. <i>Science Advances</i> . 2021, 7, .	11.3	20
12	The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2020, 215, 314-321.	2.4	6
13	Liver Enzyme CYP2D6 Gene and Tardive Dyskinesia. <i>Pharmacogenomics</i> , 2020, 21, 1065-1072.	1.8	6
14	M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN. <i>Schizophrenia Bulletin</i> , 2020, 46, S202-S202.	4.3	0
15	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. <i>Frontiers in Pharmacology</i> , 2020, 11, .	4.0	15
16	Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 190, 172872.	2.4	15
17	Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 240-249.	2.0	35
18	Unmet Needs in Patients with Schizophrenia. , 2020, , 15-25.		0

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. <i>Schizophrenia Research</i> , 2019, 212, 204-212.	2.4	17
20	The Role of Dopamine D <sub>3</sub> Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 517-525.	3.5	25
21	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109659.	4.1	9
22	Association of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, .	2.7	13
23	Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. <i>Journal of Neuroscience</i> , 2019, 39, 1982-1993.	3.7	64
24	The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. <i>Behavioural Brain Research</i> , 2019, 361, 139-150.	2.3	22
25	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 91-95.	3.9	7
26	A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. <i>Pharmacogenomics Journal</i> , 2019, 20, 260-270.	3.1	16
27	Hippocampal GABA A antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats. <i>Behavioural Brain Research</i> , 2018, 342, 11-18.	2.3	5
28	Dissecting the Functional Consequences of De Novo DNA Methylation Dynamics in Human Motor Neuron Differentiation and Physiology. <i>Cell Stem Cell</i> , 2018, 22, 559-574.e9.	17.2	51
29	Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. <i>Schizophrenia Research</i> , 2018, 192, 194-204.	2.4	62
30	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2018, 19, S97-S105.	3.9	11
31	F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS. <i>Schizophrenia Bulletin</i> , 2018, 44, S218-S218.	4.3	0
32	Investigation of the HSPC2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, .	4.0	18
33	T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA – A FOLLOW-UP ON THE VALBENZAZINE TARGET VMAT2/SLC18A2. <i>Schizophrenia Bulletin</i> , 2018, 44, S115-S115.	4.3	0
34	5-HT1A partial agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA. <i>Psychopharmacology</i> , 2018, 235, 2795-2808.	3.0	21
35	Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials. <i>Schizophrenia Research</i> , 2018, 199, 203-213.	2.4	16
36	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , 2018, 686, 17-22.	1.9	6

#	ARTICLE	IF	CITATIONS
37	TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia. <i>Neuropsychopharmacology</i> , 2018, 43, 2468-2477.	5.4	13
38	A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 641-651.	5.1	6
39	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. <i>Journal of Neural Transmission</i> , 2018, 126, 27-33.	3.6	12
40	Association study between the neurexin-1 gene and tardive dyskinesia. <i>Human Psychopharmacology</i> , 2017, 32, .	1.9	6
41	Dopamine D <sub>4</sub> receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia. <i>Journal of Psychopharmacology</i> , 2017, 31, 442-452.	5.8	27
42	Neurochemical arguments for the use of dopamine D <sub>4</sub> receptor stimulation to improve cognitive impairment associated with schizophrenia. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 157, 16-23.	2.4	20
43	Replication of rs300774, a genetic biomarker near ACP1, associated with suicide attempts in patients with schizophrenia: Relation to brain cholesterol biosynthesis. <i>Journal of Psychiatric Research</i> , 2017, 94, 54-61.	3.1	19
44	RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. <i>Behavioural Brain Research</i> , 2017, 332, 180-199.	2.3	20
45	5-HT <sub>2C</sub> Agonists Modulate Schizophrenia-Like Behaviors in Mice. <i>Neuropsychopharmacology</i> , 2017, 42, 2163-2177.	5.4	40
46	Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats. <i>Journal of Psychopharmacology</i> , 2017, 31, 1588-1604.	5.8	14
47	Î <sup>9</sup> -tetrahydrocannabinol (Î <sup>9</sup> -THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 159, 6-11.	2.4	21
48	Reduced Glutamatergic Currents and Dendritic Branching of Layer 5 Pyramidal Cells Contribute to Medial Prefrontal Cortex Deactivation in a Rat Model of Neuropathic Pain. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, .	3.5	80
49	Phencyclidine (PCP)-Induced Deficits in Novel Object Recognition. , 2016, , 723-732.		1
50	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016, 31, 121-134.	1.9	17
51	Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U. <i>Biological Psychiatry</i> , 2016, 80, 878-887.	1.7	24
52	Preliminary Evidence for Association of Genome-Wide Significant <i>DRD2</i> Schizophrenia Risk Variant with Clozapine Response. <i>Pharmacogenomics</i> , 2016, 17, 103-109.	1.8	31
53	GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. <i>Behavioural Brain Research</i> , 2016, 299, 105-110.	2.3	41
54	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 221-229.	3.9	23

#	ARTICLE	IF	CITATIONS
55	Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. <i>Behavioural Brain Research</i> , 2016, 301, 204-212.	2.3	23
56	Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT) <sub>1A</sub> -dependent mechanism. <i>Behavioural Brain Research</i> , 2016, 301, 132-141.	2.3	13
57	Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. <i>Neuropharmacology</i> , 2016, 100, 90-97.	4.5	33
58	The Neurobiology of Schizophrenia. , 2015, , 303-319.		0
59	The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2015, 17, 528-535.	2.5	51
60	Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis. <i>Angewandte Chemie</i> , 2015, 127, 7004-7008.	1.5	6
61	A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. <i>PLoS ONE</i> , 2015, 10, e0121707.	2.5	6
62	Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory. <i>American Journal of Psychiatry</i> , 2015, 172, 502-504.	10.5	14
63	Pharmacotherapy of cognition in schizophrenia. <i>Current Opinion in Behavioral Sciences</i> , 2015, 4, 115-121.	3.4	22
64	Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 6900-6904.	15.0	25
65	Combined serotonin (5-HT) <sub>1A</sub> agonism, 5-HT <sub>2A</sub> and dopamine D <sub>2</sub> receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. <i>Behavioural Brain Research</i> , 2015, 285, 165-175.	2.3	26
66	Decreased serotonin <sub>2C</sub> receptor responses in male patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 226, 308-315.	3.4	5
67	Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor- $\beta$ (TGF- $\beta$ ) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells <i>in vitro</i> . <i>Journal of Neurochemistry</i> , 2015, 132, 418-428.	4.0	11
68	Dopamine D <sub>3</sub> receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 138, 49-57.	2.4	26
69	Serotonin (5-HT) <sub>1A</sub> receptor agonism and 5-HT <sub>7</sub> receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. <i>Psychopharmacology</i> , 2015, 233, 649-660.	3.0	26
70	A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1085-1090.	2.9	94
71	Clozapine. , 2014, , 229-236.		0
72	The novel $\pm$ 7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. <i>Psychopharmacology</i> , 2014, 231, 4541-4551.	3.0	44

#	ARTICLE	IF	CITATIONS
73	A genetic locus in 7p12.2 associated with treatment resistant schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 333-339.	2.4	23
74	Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT <sub>2A</sub> ) and DA D <sub>2</sub> antagonism and 5-HT <sub>1A</sub> partial agonism. <i>Journal of Neurochemistry</i> , 2014, 128, 938-949.	4.0	66
75	Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a $\beta$ Arrestin2-Independent Activation of Akt. <i>Neuropsychopharmacology</i> , 2014, 39, 1902-1913.	5.4	52
76	Schizophrenia and Suicide: Treatment Optimization. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 149-162.	2.3	2
77	Language-dependent performance on the letter fluency task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014, 152, 421-429.	2.4	11
78	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. <i>Psychiatry Research</i> , 2014, 219, 255-260.	3.4	12
79	Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice. <i>Neuropsychopharmacology</i> , 2014, 40, 1141-1150.	5.4	26
80	The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia. <i>Current Pharmaceutical Design</i> , 2014, 20, 5104-5114.	2.3	129
81	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1760-1765.	3.1	48
82	D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. <i>Behavioural Brain Research</i> , 2013, 238, 36-43.	2.3	37
83	Update on Typical and Atypical Antipsychotic Drugs. <i>Annual Review of Medicine</i> , 2013, 64, 393-406.	20.4	325
84	Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 2181-2194.	2.0	97
85	Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. <i>Journal of Clinical Investigation</i> , 2013, 123, 4986-4991.	9.1	92
86	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. <i>Neuropsychopharmacology</i> , 2013, 39, 1347-1354.	5.4	24
87	The alpha-7 nicotinic receptor partial agonist/5-HT <sub>3</sub> antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. <i>Psychopharmacology</i> , 2013, 231, 2199-2210.	3.0	25
88	Mechanisms of Clozapine-Induced Agranulocytosis. <i>Drug Safety</i> , 2012, 7, 17-25.	3.2	26
89	Perospirone. <i>CNS Drugs</i> , 2012, 15, 338.	6.8	0
90	Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tansospirone, a 5-HT <sub>1A</sub> Partial Agonist. <i>Neuropsychopharmacology</i> , 2012, 37, 2175-2183.	5.4	40

#	ARTICLE	IF	CITATIONS
91	The Novel Antipsychotic Drug Lurasidone Enhances $N$ -Methyl-d-aspartate Receptor-Mediated Synaptic Responses. <i>Molecular Pharmacology</i> , 2012, 81, 113-119.	2.8	32
92	5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. <i>NeuroReport</i> , 2012, 23, 436-440.	1.5	41
93	Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. <i>Schizophrenia Research</i> , 2012, 141, 144-152.	2.4	79
94	Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 202-206.	3.4	19
95	Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 62-75.	4.1	30
96	Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012, , 87-124.	0.0	88
97	Clozapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2012, 6, 134-144.	1.1	178
98	Association of FAS, a TNF- $\alpha$ receptor gene, with treatment resistant schizophrenia. <i>Schizophrenia Research</i> , 2011, 129, 211-212.	2.4	9
99	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. <i>Schizophrenia Research</i> , 2011, 132, 121-124.	2.4	25
100	5-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine efflux—Studied in 5-HT2A and 5-HT2C genetic mutant mice. <i>European Journal of Pharmacology</i> , 2011, 652, 40-45.	4.4	20
101	The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. <i>Psychopharmacology</i> , 2011, 213, 289-305.	3.0	105
102	Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. <i>Psychopharmacology</i> , 2011, 217, 13-24.	3.0	56
103	Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. <i>American Journal of Psychiatry</i> , 2011, 168, 957-967.	10.5	220
104	A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1602-1610.	2.9	38
105	Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. <i>Human Psychopharmacology</i> , 2010, 25, 582-585.	1.9	17
106	Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data. <i>Schizophrenia Research</i> , 2010, 122, 38-42.	2.4	173
107	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 286-293.	3.4	22
108	Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 948-955.	3.5	21

#	ARTICLE	IF	CITATIONS
109	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. <i>PLoS Genetics</i> , 2009, 5, e1000373.	3.3	353
110	Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. <i>Psychopharmacology</i> , 2009, 205, 119-128.	3.0	233
111	Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function. <i>Psychiatry Research</i> , 2009, 169, 178-179.	3.4	38
112	Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. <i>Neuropsychopharmacology</i> , 2009, 35, 881-892.	5.4	250
113	Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylozapine. <i>European Journal of Pharmacology</i> , 2008, 596, 89-97.	4.4	18
114	Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2008, 106, 258-264.	2.4	29
115	Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?. <i>Behavioural Brain Research</i> , 2008, 195, 98-102.	2.3	151
116	Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. <i>Pharmacological Reviews</i> , 2008, 60, 358-403.	16.4	200
117	Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus. <i>Neuropsychopharmacology</i> , 2008, 33, 2934-2945.	5.4	43
118	Oakley Ray, 1931â€“2007. <i>Neuropsychopharmacology</i> , 2008, 33, 2783-2784.	5.4	0
119	In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. <i>Progress in Brain Research</i> , 2008, , 177-197.	0.0	202
120	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 392-400.	2.0	80
121	The Neurobiology of Schizophrenia. , 2008, , 301-316.		8
122	A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 274-285.	2.9	126
123	Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3019-3020.	7.7	20
124	WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 486-496.	3.5	132
125	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	14.4	895
126	Atypical Antipsychotic Drugs: Mechanism of Action. , 2007, , .		0

#	ARTICLE	IF	CITATIONS
127	A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. <i>Schizophrenia Research</i> , 2007, 89, 211-224.	2.4	120
128	5-HT <sub>6</sub> receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. <i>Brain Research</i> , 2007, 1134, 70-78.	2.5	54
129	Aripiprazole for Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 213-223.	2.9	99
130	Testing multiple novel mechanisms for treating schizophrenia in a single trial. , 2006, , 115-120.		1
131	Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know. <i>CNS Spectrums</i> , 2006, 11, 14-24.	0.7	35
132	Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. <i>Brain Research</i> , 2006, 1099, 44-55.	2.5	30
133	Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 115-120.	0.1	0
134	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610.	10.5	740
135	The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 153-156.	2.0	23
136	ACP-103, a 5-HT <sub>2A/2C</sub> inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. <i>Psychopharmacology</i> , 2005, 183, 144-153.	3.0	53
137	Association study of 12 polymorphisms spanning the dopamine D <sub>2</sub> receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. <i>Psychopharmacology</i> , 2005, 181, 179-187.	3.0	81
138	A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 457-472.	2.0	506
139	A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 63-72.	2.9	153
140	Suicide in Schizophrenia, Clozapine, and Adoption of Evidence-Based Medicine. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 530-533.	2.9	46
141	Serotonin 1A Receptors in Memory Function. <i>American Journal of Psychiatry</i> , 2004, 161, 1505-1505.	10.5	26
142	Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment. <i>CNS Spectrums</i> , 2004, 9, 15-24.	0.7	51
143	Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 975-984.	10.5	296
144	Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. <i>European Journal of Pharmacology</i> , 2004, 493, 75-83.	4.4	168

#	ARTICLE	IF	CITATIONS
145	Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. <i>Brain Research</i> , 2004, 1023, 54-63.	2.5	77
146	Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease. <i>Neuropsychopharmacology</i> , 2003, 12, 39-45.	5.4	28
147	Atypical antipsychotic drugs improve cognition in schizophrenia. <i>Biological Psychiatry</i> , 2003, 53, 265-267.	1.7	32
148	Clozapine-induced weight gain predicts improvement in psychopathology. <i>Schizophrenia Research</i> , 2003, 59, 19-27.	2.4	112
149	Serotonin receptors : their key role in drugs to treat schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1159-1172.	4.1	636
150	H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs. <i>Neuropsychopharmacology</i> , 2003, 28, 519-526.	5.4	665
151	Clozapine Treatment for Suicidality in Schizophrenia&lt;sub>title&gt;International Suicide Prevention Trial (InterSePT)&lt;/sub>. <i>Archives of General Psychiatry</i> , 2003, 60, 82.	14.4	1,128
152	Reply: H1-histamine Receptor Affinity Predicts Short-term Weight Gain for Typical and Atypical Antipsychotic Drugs. <i>Neuropsychopharmacology</i> , 2003, 28, 2210-2211.	5.4	4
153	Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes. <i>CNS Spectrums</i> , 2003, 8, 16-18.	0.7	8
154	5-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. <i>Brain Research</i> , 2002, 939, 34-42.	2.5	46
155	5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. <i>Brain Research</i> , 2002, 947, 157-165.	2.5	113
156	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. <i>Brain Research</i> , 2002, 956, 349-357.	2.5	196
157	Response&lt;sub>title&gt;Neuropsychopharmacology, 2002, 26, 409.	5.4	0
158	SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens. <i>Neuropsychopharmacology</i> , 2002, 27, 430-441.	5.4	66
159	Commentary on "Clinical studies on the mechanism of action of clozapine; the dopamine&lt;sub>title&gt;serotonin hypothesis of schizophrenia." <i>Psychopharmacology</i> (1989) 99:S18&lt;sub>title&gt;S27. <i>Psychopharmacology</i> , 2002, 163, 1-3.	3.0	35
160	The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. <i>Biological Psychiatry</i> , 2001, 49, 861-868.	1.7	143
161	5&lt;sub>title&gt;HT&lt;sub>title&gt;2A&lt;/sub> and D&lt;sub>title&gt;2&lt;/sub> receptor blockade increases cortical DA release via 5&lt;sub>title&gt;HT&lt;sub>title&gt;1A&lt;/sub> receptor activation: a possible mechanism of atypical antipsychotic&lt;sub>title&gt;induced cortical dopamine release. <i>Journal of Neurochemistry</i> , 2001, 76, 1521-1531.	4.0	457
162	Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment. <i>American Journal of Psychiatry</i> , 2001, 158, 1722-1725.	10.5	187

#	ARTICLE	IF	CITATIONS
163	Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum. <i>Neuropsychopharmacology</i> , 2001, 26, 325-339.	5.4	206
164	Treatment of Suicidality in Schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2001, 932, 44-60.	4.5	95
165	Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. <i>Psychopharmacology</i> , 2000, 150, 349-350.	3.0	62
166	Effect of Adjunctive Treatment With Serotonin-1A Agonist Tansospirone on Memory Functions in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 386-388.	2.0	60
167	Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. <i>Psychopharmacology</i> , 1999, 144, 255-263.	3.0	26
168	Association of the Mscl Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia. <i>Neuropsychopharmacology</i> , 1999, 21, 17-27.	5.4	129
169	Brain Noradrenergic Receptors in Major Depression and Schizophrenia. <i>Neuropsychopharmacology</i> , 1999, 21, 69-81.	5.4	66
170	The Role of Serotonin in Antipsychotic Drug Action. <i>Neuropsychopharmacology</i> , 1999, 21, 106S-115S.	5.4	578
171	Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S90-S98.	2.9	133
172	Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. <i>European Journal of Pharmacology</i> , 1998, 351, 163-171.	4.4	73
173	Effects of Desmethylclozapine on Fos Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine Metabolite. <i>Neuropsychopharmacology</i> , 1998, 19, 99-103.	5.4	23
174	Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 1998, 19, 123-132.	5.4	202
175	The Evolution of Treatment Resistance: Biologic Implications. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 5S-11S.	2.0	24
176	INTRODUCTION. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 1S.	2.0	5
177	Treatment-Resistant Schizophrenia - The Role of Clozapine. <i>Current Medical Research and Opinion</i> , 1997, 14, 1-20.	2.2	383
178	Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. <i>Psychiatry Research</i> , 1997, 66, 1-11.	3.4	296
179	Serotonin Receptors in Suicide Victims with Major Depression. <i>Neuropsychopharmacology</i> , 1997, 16, 162-173.	5.4	130
180	The Effect of Streptozotocin-Induced Diabetes on Dopamine <sub>2</sub> , Serotonin <sub>1A</sub> and Serotonin <sub>2A</sub> Receptors in the Rat Brain. <i>Neuropsychopharmacology</i> , 1997, 16, 183-190.	5.4	35

#	ARTICLE	IF	CITATIONS
181	Fluoxetine, but not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-Mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder. <i>Neuropsychopharmacology</i> , 1997, 17, 1-11.	5.4	57
182	Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. <i>Psychiatry Research</i> , 1996, 64, 147-159.	3.4	19
183	Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review. <i>British Journal of Psychiatry</i> , 1996, 168, 23-31.	2.3	59
184	Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. <i>Brain Research</i> , 1996, 708, 209-214.	2.5	149
185	Cloning, Characterization, and Chromosomal Localization of a Human 5-HT <sub>6</sub> Serotonin Receptor. <i>Journal of Neurochemistry</i> , 1996, 66, 47-56.	4.0	323
186	Dr. Meltzer and Mr. Cola Reply. <i>American Journal of Psychiatry</i> , 1995, 152, 153-154.	10.5	127
187	Association study between the dopamine D4 receptor gene and schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 452-455.	0.6	48
188	Association study of dopamine D3 receptor gene and schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 558-562.	0.6	46
189	Plasma Clozapine and Desmethylclozapine Levels in Clozapine-Induced Agranulocytosis. <i>Neuropsychopharmacology</i> , 1994, 11, 45-47.	5.4	33
190	Effect of Clozapine Treatment on Serotonin-2 <sup>α</sup> Receptor Binding in the Blood Platelets of Schizophrenic Patients. <i>Neuropsychopharmacology</i> , 1994, 10, 109-114.	5.4	13
191	The Effect of Apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and Placebo on Smooth Pursuit Gain and Corrective Saccades in Normal Subjects. <i>Neuropsychopharmacology</i> , 1994, 11, 49-62.	5.4	13
192	N <sup>α</sup> -desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. <i>British Journal of Haematology</i> , 1994, 86, 555-561.	2.7	85
193	Blunted oral body temperature response to MK-212 in cocaine addicts. <i>Drug and Alcohol Dependence</i> , 1994, 35, 217-222.	3.1	18
194	Recent advances in the pharmacotherapy of schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1994, 90, 95-101.	4.7	56
195	RELATIONSHIP BETWEEN POSITIVE AND NEGATIVE SYMPTOMS: RESPONSE TO ANTIPSYCHOTIC DRUGS AND STRUCTURAL BRAIN ABNORMALITIES. , 1994, , 430-434.		0
196	Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. <i>Biological Psychiatry</i> , 1993, 34, 702-712.	1.7	340
197	Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. <i>Biological Psychiatry</i> , 1992, 31, 460-470.	1.7	18
198	The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. <i>Brain Research</i> , 1992, 574, 98-104.	2.5	32

#	ARTICLE	IF	CITATIONS
199	Amperozide, a Novel Antipsychotic Drug, Inhibits the Ability of d-Amphetamine to Increase Dopamine Release In Vivo in Rat Striatum and Nucleus Accumbens. <i>Journal of Neurochemistry</i> , 1992, 58, 2285-2291.	4.0	53
200	Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. <i>Psychopharmacology</i> , 1991, 103, 258-264.	3.0	53
201	Effect of 3,4-Methylenedioxyamphetamine on 3,4-Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens. <i>Journal of Neurochemistry</i> , 1990, 54, 1062-1067.	4.0	47
202	Serotonergic Dysfunction in Depression. <i>British Journal of Psychiatry</i> , 1989, 155, 25-31.	2.3	189
203	Selective cross-tolerance to 5-HT <sub>1A</sub> and 5-HT <sub>2</sub> receptor-mediated temperature and corticosterone responses. <i>Pharmacology Biochemistry and Behavior</i> , 1989, 33, 781-785.	2.4	38
204	Basic biology of clozapine: electrophysiological and neuroendocrinological studies. <i>Psychopharmacology</i> , 1989, 99, S13-S17.	3.0	36
205	Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. <i>Psychopharmacology</i> , 1989, 99, S18-S27.	3.0	518
206	Clozapine: New research on efficacy and mechanism of action. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1989, 238, 332-339.	0.9	90
207	Effect of typical and atypical antipsychotic drugs on 5-HT <sub>2</sub> receptor density in rat cerebral cortex. <i>Life Sciences</i> , 1989, 45, 1397-1406.	4.5	77
208	Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. <i>Acta Psychiatrica Scandinavica</i> , 1989, 80, 24-29.	4.7	27
209	Duration of a Clozapine Trial in Neuroleptic-Resistant Schizophrenia. <i>Archives of General Psychiatry</i> , 1989, 46, 672.	14.4	64
210	Novel approaches to the pharmacotherapy of schizophrenia. <i>Drug Development Research</i> , 1986, 9, 23-40.	3.5	30
211	Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. <i>Psychopharmacology</i> , 1986, 90, .	3.0	21
212	Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin <sub>2</sub> Receptors in Rat Cerebral Cortex. <i>Journal of Neurochemistry</i> , 1986, 46, 191-197.	4.0	80
213	Descriptive studies of H-reflex recovery curves in psychiatric patients. <i>Psychological Medicine</i> , 1980, 10, 541-548.	4.6	23
214	Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotypes behavior and ataxia in rats. <i>European Journal of Pharmacology</i> , 1979, 59, 169-179.	4.4	224
215	Serum Creatine Phosphokinase Activity in Acute Psychosis. <i>British Journal of Psychiatry</i> , 1973, 122, 369-369.	2.3	0
216	Muscle Abnormalities in Acute Psychoses. <i>Archives of General Psychiatry</i> , 1970, 23, 481.	14.4	59

#	ARTICLE	IF	CITATIONS
217	Awareness of illness moderates self-assessment of psychotic symptoms. Australian and New Zealand Journal of Psychiatry, 0, , 000486742110574.	2.7	1